Other Science

Lucid Diagnostics Provides Business Update and Preliminary Second Quarter 2022 Financial Results

Retrieved on: 
Monday, August 15, 2022 - 9:25pm

Lucid Diagnostics Inc. (Nasdaq: LUCD) (Lucid, the Company), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (PAVmed), today provided a business update for the Company and presented preliminary financial results for the three and six months ended June 30, 2022.

Key Points: 
  • Lucid Diagnostics Inc. (Nasdaq: LUCD) (Lucid, the Company), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (PAVmed), today provided a business update for the Company and presented preliminary financial results for the three and six months ended June 30, 2022.
  • A conference call and webcast for todays business update and second quarter 2022 financial results will take place at 4:30 PM EDT.
  • The laboratory processed 850 commercial EsoGuard tests in the second quarter of 2022, which represents a 60% increase sequentially from the first quarter of 2022 and an over 300% increase annually from the second quarter of 2021.
  • To supplement our unaudited financial results presented in accordance with U.S. generally accepted accounting principles (GAAP), management provides certain non-GAAP financial measures of the Companys financial results.

Xlear Files Amended Answer to the Government’s Lawsuit on COVID-19 Statements; Provides Still More Data In Support of Xlear’s Use as Additional Layer of Protection

Retrieved on: 
Monday, August 15, 2022 - 6:42pm

Nate Jones, CEO of Xlear noted, The Government agrees, Xlear is a saline nasal solution.

Key Points: 
  • Nate Jones, CEO of Xlear noted, The Government agrees, Xlear is a saline nasal solution.
  • New in silico research determined that compounds of grapefruit seed extract (GSE) were effective inhibitors of the SARS-CoV-2 virus.
  • Most importantly, these experts concluded natural GSEwhich is a component of Xlearwas more effective than synthetic versions of the compound.
  • As part of its efforts to silence Xlear, the Government asked the Utah Federal Court to preclude Xlear from filing the Amended Answer.

Applications now open for 2023-24 Albert Einstein Distinguished Educator Fellowship

Retrieved on: 
Monday, August 15, 2022 - 6:05pm

Applications are open now for the 2023-2024 Albert Einstein Distinguished Educator Fellowship.

Key Points: 
  • Applications are open now for the 2023-2024 Albert Einstein Distinguished Educator Fellowship.
  • Einstein Fellows bring their extensive classroom knowledge and experience to their host offices to inform federal STEM education efforts.
  • Program applications must be submitted by November 18, 2022, at 8 p.m. EST through the online application system.
  • The Einstein Fellowship program is administered by DOEOffice of Science and coordinated by the Oak Ridge Institute for Science and Education (ORISE).

Global Industrial Water Treatment Equipment Market Analysis Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Monday, August 15, 2022 - 4:59pm

This study identifies the innovation in water treatment technologies as one of the prime reasons driving the industrial water treatment equipment market growth during the next few years.

Key Points: 
  • This study identifies the innovation in water treatment technologies as one of the prime reasons driving the industrial water treatment equipment market growth during the next few years.
  • Also, research on photocatalytic water treatment processes for industrial water treatment and smart wastewater treatment management will lead to sizable demand in the market.
  • The report on the industrial water treatment equipment market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
  • Also, the industrial water treatment equipment market analysis report includes information on upcoming trends and challenges that will influence market growth.

Pioneering Engineer-Researcher to Receive 2022 Szent-Györgyi Prize for Progress in Cancer Research

Retrieved on: 
Monday, August 15, 2022 - 2:00pm

The National Foundation for Cancer Research (NFCR) announced today that Rakesh K. Jain, Ph.D., has been selected to receive the 2022 Szent-Gyrgyi Prize for Progress in Cancer Research.

Key Points: 
  • The National Foundation for Cancer Research (NFCR) announced today that Rakesh K. Jain, Ph.D., has been selected to receive the 2022 Szent-Gyrgyi Prize for Progress in Cancer Research.
  • Dr. Rakesh Jains seminal discoveries in basic and translational research have guided numerous fields in cancer research with the promise of saving lives.
  • These are the pillars of the Szent-Gyrgyi Prize, said Sujuan Ba, Ph.D., co-chair of the 2022 Prize selection committee and President and CEO of NFCR.
  • The Szent-Gyrgyi Prize for Progress in Cancer Research was established by the National Foundation for Cancer Research in honor of its co-founder, Albert Szent-Gyrgyi, M.D., Ph.D., recipient of the 1937 Nobel Prize for Physiology and Medicine.

 Virpax Pharmaceuticals Reports 2022 Second Quarter Results and Recent Developments

Retrieved on: 
Monday, August 15, 2022 - 2:00pm

Virpax Pharmaceuticals, Inc. (Virpax or the Company) (NASDAQ:VRPX), a company specializing in developing non-addictive product candidates for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced its financial results for the quarter ended June 30, 2022, and other recent developments.

Key Points: 
  • Virpax Pharmaceuticals, Inc. (Virpax or the Company) (NASDAQ:VRPX), a company specializing in developing non-addictive product candidates for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced its financial results for the quarter ended June 30, 2022, and other recent developments.
  • FINANCIAL RESULTS FOR THE THREE ENDED JUNE 30, 2022 AND 2021
    Three Months Ended June 30, 2022 and 2021
    General and administrative expenses were approximately $2.7 million for the second quarter of 2022, an increase of about $0.7 million from the prior years second quarter.
  • Research and development expenses were approximately $3.3 million in the quarter compared to approximately $0.3 million from the prior years second quarter.
  • The operating loss for the second quarter of 2022 was approximately $5.9 million, as compared to $2.3 million for the same period a year ago.

Columbia Care Reports Second Quarter 2022 Results

Retrieved on: 
Monday, August 15, 2022 - 12:30pm

In addition, the Company expects sequential improvements in market level EBITDA margin in the range of 150-250 basis points per quarter compared to our YTD results.

Key Points: 
  • In addition, the Company expects sequential improvements in market level EBITDA margin in the range of 150-250 basis points per quarter compared to our YTD results.
  • At this time, Columbia Cares 2022 outlook does not assume any additional changes in the regulatory environment in markets where Columbia Care currently operates.
  • ET to discuss financial and operating results for the second quarter.
  • Columbia Care operates 131 facilities including 99 dispensaries and 32 cultivation and manufacturing facilities, including those under development.

Monod Bio Closes $25M Seed Financing to Advance Biosensor Technology Platform

Retrieved on: 
Monday, August 15, 2022 - 1:00pm

Monod Bio , a life sciences company developing custom diagnostic biosensors that emit light to detect specific biomolecules of interest, today announced it has raised a $25M seed financing round.

Key Points: 
  • Monod Bio , a life sciences company developing custom diagnostic biosensors that emit light to detect specific biomolecules of interest, today announced it has raised a $25M seed financing round.
  • Monod was founded in November 2021 from technology developed at David Bakers lab at the University of Washington Institute for Protein Design.
  • Our partnership with Monod Bio reflects our commitment to back extraordinary teams unlocking breakthrough innovation at the intersection of technology and life sciences.
  • Monod Bio's innovative biosensor platform technology uses computational protein engineering to create highly modular biosensing nanoswitches that enable rapid, sensitive, and cost-effective analytical assays.

Applied UV Files Trademark Infringement Lawsuit Against Aeroclean Technologies

Retrieved on: 
Monday, August 15, 2022 - 1:00pm

Applied UV, Inc. (NasdaqCM: AUVI ) (Applied UV or the Company), a pathogen elimination technology company that applies the power of narrow-range ultraviolet light (UVC) for surface areas and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly, and automatically, today announced that its wholly-owned subsidiary, Sterilumen, Inc. , has filed a lawsuit in the amount of $20 million against Aeroclean Technologies, Inc. (NASDAQ: AERC) and its predecessor, Aeroclean Technologies, LLC, for trademark infringement, unfair competition and damaging Sterilumen.

Key Points: 
  • Applied UV, Inc. (NasdaqCM: AUVI ) (Applied UV or the Company), a pathogen elimination technology company that applies the power of narrow-range ultraviolet light (UVC) for surface areas and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly, and automatically, today announced that its wholly-owned subsidiary, Sterilumen, Inc. , has filed a lawsuit in the amount of $20 million against Aeroclean Technologies, Inc. (NASDAQ: AERC) and its predecessor, Aeroclean Technologies, LLC, for trademark infringement, unfair competition and damaging Sterilumen.
  • John F. Andrews, Applied UVs CEO and Director, stated, Protecting our brand, Airoclean , and trademarked products and technologies is crucial, and we will vigorously defend against infringements.
  • Applied UV is focused on the development and acquisition of technology that address infection control in the healthcare, hospitality, commercial and municipal markets.
  • For more information about Applied UV, Inc., and its subsidiaries, please visit the following websites: https://www.applieduvinc.com/
    The information contained herein may contain forwardlooking statements.

IQVIA Wins Snowflake’s “Marketplace Healthcare and Life Sciences Partner of the Year” Award

Retrieved on: 
Monday, August 15, 2022 - 12:30pm

IQVIA (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and contract services to the life sciences industry, today announced it has been named the 2022 Marketplace Healthcare and Life Sciences Partner of the Year by Snowflake, the Data Cloud company.

Key Points: 
  • IQVIA (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and contract services to the life sciences industry, today announced it has been named the 2022 Marketplace Healthcare and Life Sciences Partner of the Year by Snowflake, the Data Cloud company.
  • IQVIA and Snowflakes collaboration brings together health and life sciences leading analytics assets, said Avinob Roy, IQVIA vice president and general manager, Global Information Management.
  • The combination of these technologies provides clients with faster insights that drive healthcare forward and accelerate improvements in healthcare outcomes.
  • IQVIA and Snowflake have made meaningful strides together in the healthcare and life sciences space, working toward helping our customers meaningfully apply their data, said Kieran Kennedy, Head of Marketplace, Snowflake.